1/17. Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.A 28 year-old man with chronic hepatitis B was administered interferon-alpha (5 x 10(6) IU) intramuscularly once a day for 28 days. Eight days after the end of interferon treatment, he showed signs of inability to sit still for ten seconds and walked around constantly. His akathisia symptoms worsened thereafter. clonazepam, thioridazine, beta-blockers, anticholinergics, and bromocriptine did not ameliorate his akathisia. Two days' administration of levomepromazine 100 mg led him to a coma for 2 days. Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically. He became completely premorbid 2 weeks after administration of levodopa. The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.- - - - - - - - - - ranking = 1keywords = administration (Clic here for more details about this article) |
2/17. lamivudine as an alternative therapy for interferon-resistant chronic hepatitis B and the characteristics of hepatitis b virus: a case report.A 27-year-old man who had been diagnosed as having chronic hepatitis B suffered disease exacerbation with marked reactivation of hepatitis b virus (HBV). Treatment with interferon (IFN) did not improve his condition, and his serum HBV dna level increased to over 10 000 pg/ml during IFN administration. Following replacement with lamivudine, there was a substantial reduction in HBV dna to an undetectable level, and liver function parameters subsequently improved to within the normal range. Quantitative analysis of the precore mutant HBV dna, which is a variant that cannot express hepatitis B e antigen due to a G-to-A point mutation in the precore region of the viral genome, revealed that the amount present was greater than for the precore wild-type HBV dna in the serum taken before IFN treatment. This case suggests that lamivudine would be an appropriate alternative to IFN, particularly in patients infected with HBV containing an excess of precore mutants resistant to IFN therapy.- - - - - - - - - - ranking = 0.16666666666667keywords = administration (Clic here for more details about this article) |
3/17. Manifestation of cutaneous polyarteritis nodosa during interferon therapy for chronic hepatitis c associated with primary biliary cirrhosis.Interferon alpha-2b was administered to a 50-year-old Japanese woman with chronic hepatitis c associated with primary biliary cirrhosis. Two months after the beginning of the interferon alpha-2b therapy a systemic nodular, erythematous rash developed. Histological analysis of the skin revealed typical features of necrotizing arteritis. Because there was no microhematuria, and no microaneurysms were detected on abdominal angiography, a diagnosis of cutaneous polyarteritis nodosa was made. A good outcome was achieved after interferon alpha-2b was discontinued and prednisolone was administered instead. The cutaneous polyarteritis nodosa in this patient is thus considered to have occurred as an adverse effect of interferon administration. To our knowledge, this is the first reported case of cutaneous polyarteritis nodosa which developed because of interferon therapy for chronic hepatitis c associated with primary biliary cirrhosis.- - - - - - - - - - ranking = 0.16666666666667keywords = administration (Clic here for more details about this article) |
4/17. Reactivation of chronic hepatitis B infection following intensive chemotherapy and successful treatment with lamivudine: a case report and review of the literature.BACKGROUND: hepatitis b virus reactivation has been reported in cancer patients following administration of chemotherapy or immunosuppressive therapy and may result in liver damage of varying degrees of severity. Although treatment is supportive in nature, lamivudine, a nucleoside analogue has been found to suppress HBV replication as evidenced by reports of 13 cases in the medical literature. patients AND methods: We report a patient who achieved a successful outcome with lamivudine following reactivation of HBV during combination chemotherapy for non-Hodgkin's lymphoma, and provide a brief overview of the literature including the 13 published case reports. RESULTS: lamivudine therapy resulted in clinical improvement as well as in normalization of liver function tests and coagulation profile. CONCLUSIONS: lamivudine has been found to suppress HBV replication manifested both by histology and serum HBV-dna levels in chronic carriers of HBV who developed reactivation of hepatic disease following chemotherapy. physicians caring for such patients should be able to recognize this clinical challenge, and lamivudine should be considered.- - - - - - - - - - ranking = 0.16666666666667keywords = administration (Clic here for more details about this article) |
5/17. Thiamine treatment of chronic hepatitis B infection.OBJECTIVE: Chronic hepatitis B is an international health concern that causes cirrhosis, hepatocellular carcinoma, liver failure, and death. Current treatment options are expensive and associated with side effects; however, indirect evidence suggests a relationship between relative thiamine deficiency and chronic hepatitis B infection. methods: The authors present three case studies wherein multiple crossovers of daily thiamine administration were used to evaluate a hypothesized association between thiamine treatment and aminotransferase levels. RESULTS: In each case study, thiamine administration was associated with reduction in aminotransferase levels and the fall of HBV dna to undetectable levels. Analyses by t test demonstrated a statistically significant reduction in aminotransferase levels in all three cases. CONCLUSIONS: The relationship between thiamine administration and chronic hepatitis B infection warrants further study. If proven effective in reducing liver damage or inducing remission of the hepatitis b virus in larger trials, thiamine will offer obvious advantages over the current treatments for chronic viral hepatitis B infection.- - - - - - - - - - ranking = 0.5keywords = administration (Clic here for more details about this article) |
6/17. Development of glaucoma in the course of interferon alpha therapy for chronic hepatitis B.Previous reported ocular complications of interferon alfa administration are extremely rare. These include oculomotor palsy, corneal allograft rejection, retinal hemorrhage and cotton wool patches. A 15-year-old boy with chronic hepatitis B was treated with interferon alpha for six months, and then developed glaucoma. After the interferon therapy had been discontinued the glaucoma improved. Accordingly, we report a case of glaucoma development during the course of interferon alpha therapy for chronic hepatitis B.- - - - - - - - - - ranking = 0.16666666666667keywords = administration (Clic here for more details about this article) |
7/17. A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.polymyositis is a rare complication of interferon alpha treatment as a result of immune-modulating role of the drug itself. In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B. To treat hepatitis B, interferon alpha was administered until the proximal muscle weakness developed. Thereafter, sixteen cycles of immunoglobulin treatment (400 mg/kg) along with corticosteroids were instituted and led to an improvement in subjective symptoms with decreases in level of CPK and LDH. However, dilated cardiomyopathy has not improved in spite of the cessation of interferon treatment. Unlike the persistently elevated serum HBV dna level, the serum ALT and AST levels have gradually decreased. Our case shows that clinical symptoms of polymyositis improved with steroid and immunoglobulin treatment without deterioration of the hepatitis B. To our knowledge, this is the first case of polymyositis associated with dilated cardiomyopathy after the administration of interferon in a patient with hepatitis B.- - - - - - - - - - ranking = 0.16666666666667keywords = administration (Clic here for more details about this article) |
8/17. Limited efficacy of lamivudine against hepatitis b virus infection in allogeneic hematopoietic stem cell transplant recipients.BACKGROUND: Reactivation of chronic hepatitis b virus (HBV) infection is a major complication when HBV carriers receive immunosuppressive therapy. Recipients of allogeneic hematopoietic stem cell transplantation (HSCT) carry the highest risk of fatal HBV disease (up to 12%). methods: In an attempt to identify a suitable procedure for the prevention and management of HBV reactivation, the administration of lamivudine over the course was tested in two patients. RESULTS: Generally, the patients transplant courses were successfully managed despite their difficult clinical situations: a high HBV load before transplant in one patient and intense steroid therapy for complicated acute graft-versus-host disease (GVHD) in the other patient. However, one patient showed a reactivation of HBV after discontinuing lamivudine and the other showed persistently high dna polymerase activity despite prolonged administration of lamivudine. CONCLUSIONS: We concluded that lamivudine could have a place in the management of patients who suffer from chronic HBV infection and who are undergoing allogeneic HSCT. However, the efficacy of lamivudine seemed to be limited compared with other settings, including solid organ transplantation and autologous HSCT.- - - - - - - - - - ranking = 0.33333333333333keywords = administration (Clic here for more details about this article) |
9/17. Acute clinical hepatitis by immune restoration in a human immunodeficiency virus/hepatitis b virus co-infected patient receiving antiretroviral therapy.We describe a human immunodeficiency virus (hiv)-infected patient with chronic active hepatitis B. The patient presented with acute clinical hepatitis during highly active antiretroviral therapy concomitant with immunovirological improvement of hiv infection. The hepatitis resolved within a few weeks despite the pursuit of antiretroviral drugs. Hepatitis B tests, which remained unchanged after two cycles of interferon alfa therapy and continuous administration of lamivudine, were improved with the clearance of hepatitis b virus (HBV) early antigen (HBeAg), the detection of antibody to HBV early antigen (HBeAb) and the undetectability of serum HBV dna. Several months after this episode, HBV and hiv tests are still controlled.- - - - - - - - - - ranking = 0.16666666666667keywords = administration (Clic here for more details about this article) |
10/17. Chronic hepatitis B with flare due to co-infection of hepatitis delta virus during lamivudine therapy.In 1997, a 27-year-old homosexual man contracted acute hepatitis B that developed into chronic hepatitis. Because of repeated flares, administration of lamivudine was started in March 2002. hepatitis b virus (HBV) dna immediately decreased, but the serum level of alanine aminotransferase gradually increased. Drug-induced hepatitis due to lamivudine was excluded. It was suspected that the progression of liver damage was caused by hepatitis delta virus (HDV), because the patient was positive for both anti-HDV antibody and HDV rna. Co-infection of HDV should be considered a possibility if liver injury is not improved by lamivudine therapy.- - - - - - - - - - ranking = 0.16666666666667keywords = administration (Clic here for more details about this article) |
| | Next -> |